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Summary
The human epithelial mucin MUC1 is a heavily glycosylated transmembrane protein that is
overexpressed and aberrantly glycosylated on over 90% of human breast cancers. The altered
glycosylation of MUC1 reveals an immunodominant peptide along its tandem repeat (TR) that
has been used as a target for tumour immunotherapy. In this study, we used the MUC1 TR
peptide as a test antigen to determine whether a plant-expressed human tumour-associated
antigen can be successfully expressed in a plant system and whether it will be able to break
self-antigen tolerance in a MUC1-tolerant mouse model. We report the expression of MUC1
TR peptide fused to the mucosal-targeting Escherichia coli enterotoxin B subunit (LTB-MUC1)
in a plant host. Utilizing a rapid viral replicon transient expression system, we obtained high
yields of LTB-MUC1. Importantly, the LTB-MUC1 fusion protein displayed post-translational
modifications that affected its antigenicity. Glycan analysis revealed that LTB-MUC1 was
glycosylated and a MUC1-specific monoclonal antibody detected only the glycosylated forms.
A thorough saccharide analysis revealed that the glycans are tri-arabinans linked to hydroxy-
prolines within the MUC1 tandem repeat sequence. We immunized MUC1-tolerant mice
(MUC1.Tg) with transiently expressed LTB-MUC1, and observed production of anti-MUC1
serum antibodies, indicating breach of tolerance. The results indicate that a plant-derived
human tumour-associated antigen is equivalent to the human antigen in the context of
immune recognition.
Introduction
The human epithelial mucin MUC1 is a heavily glycosylated
transmembrane protein that is expressed on simple secretory
epithelial cells of ducts and glands. MUC1 is overexpressed and
aberrantly glycosylated on many human epithelial tumours,
including more than 90% of human breast cancers (Mukherjee
et al., 2003). The altered glycosylation of MUC1 on tumour
cells reveals an immunodominant peptide sequence along its
tandem repeat (TR) that has been used as a target for tumour
immunotherapy in a number of preclinical and clinical studies
(Acres et al., 1993, 2000; Ding et al., 1993; Apostolopoulos
et al., 1994; Scholl et al., 2000; Mukherjee et al., 2001, 2003,
2004; Rochlitz et al., 2003). On normal epithelial cells, MUC1 is
polarized and restricted to the apical surface of the cell,
whereas on tumour cells MUC1 is no longer restricted and is
found throughout the tumour mass. In breast cancer, MUC1
expression correlates with high metastatic potential and poor
survival (Nakamori et al., 1994; McGuckin et al., 1995; Leroy
et al., 2002). The 2009 Cancer Statistics report noted that can-
cers expressing aberrant MUC1 accounted for 72% of new
cases and 66% of the deaths (Jemal et al., 2009). The altered
expression and glycosylation pattern of MUC1 on tumour cells
makes it an attractive target for cancer immunotherapy,
especially with the recent finding that the TR of MUC1 is a
target for cytotoxic T lymphocytes (CTLs; Jerome et al., 1991;
Ioannides et al., 1993; Reddish et al., 1998). Importantly, the
lymphocytes that target the aberrant form of MUC1 do not
recognize the nonaberrant form on healthy cells and therefore
do not cause autoimmunity. However, like many other tumour-
associated antigens, MUC1 is a self-antigen that is expressed on
secretory epithelia neonatally and postnatally; thus, the T- and
B-cell repertoires are immunologically tolerant to MUC1. To
evaluate vaccines directed against MUC1 as a self-antigen,
a transgenic mouse model that expresses the human MUC1
molecule on an inbred C57BL ⁄ 6 background (MUC1.Tg) was
created. The MUC1.Tg mice carry the human MUC1 transgene
driven by its own promoter and express MUC1 in a develop-
mentally regulated and tissue-specific fashion similar to humans
(Rowse et al., 1998).
The use of plants for the production and delivery of vaccine
proteins is emerging as an attractive alternative to traditional
production systems (Tacket, 2005). Producing vaccines in plants
reduces the risk of contamination with animal pathogens and
offers the possibility for large-scale production at potentially
low costs. Vaccine antigens can be produced in plants via
stable genetic transformation or by virus-based transient expres-
sion systems. Stable genetic transformation system involves
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integrating the gene of interest into the plant genome and
allows the successive propagation of the transgenic line via
seeds or vegetative cuttings. Transient expression systems often
use a recombinant virus that carries the gene of interest and
which upon infection causes the plant to express the vaccine
antigen. Typically, transient expression produces substantially
higher expression than stable transgenic plants. Specifically, a
deconstructed viral vector system known as magnICONTM (Icon
Genetics, Halle, Germany) is based on in planta assembly of
functional viral replicons from separate pro-vector modules
(Marillonnet et al., 2004). With this system, Agrobacterium cells
are used to deliver various modules that are assembled inside
the cell with the help of a site-specific recombinase (integrase).
The resulting DNA is transcribed and spliced to remove the
recombination sites, thus generating a fully functional replicon.
With the magnICONTM expression system, GFP expression in
leaves of Nicotiana benthamiana was reported at 80% total
soluble protein (TSP; Marillonnet et al., 2004) compared to
the <1% TSP achieved with stable transgenic plants. The
magnICONTM system is rapid, generating high expression in
7–14 days postinfiltration, compared to the months required for
stable plant transformation.
Subunit vaccines consist of one or more proteins that contain
the antigenic fingerprint of the disease-causing agent but do
not cause disease. They are usually monomeric antigens that
are not particulate or conglomerate and are often poor
immunogens. Because small molecules with a molecular weight
of <2–5 kDa are not usually immunogenic, even when adminis-
tered in the presence of adjuvant, we decided to fuse the
MUC1 TR to a carrier molecule. A bacterial product with great
potential to act as a carrier for subunit vaccines is the heat-
labile toxin (LT) of enterotoxigenic Escherichia coli. LT and the
closely related Vibrio cholerae cholera toxin (CT) bind to gangli-
oside receptors on all nucleated cells and have strong immuno-
enhancing effects on both systemic and mucosal immune
responses (Rappuoli et al., 1999). LT contains a nontoxic B sub-
unit (LTB) and a toxic A subunit (LTA). The B subunit forms a
doughnut-shaped pentamer that targets the holotoxin to the
gut-associated lymphoid tissue (GALT) by binding to M cells
found on the surface of Peyer’s patches. The potent mucosal
immunogenicity of LT and LTB depends in part on the ability to
bind to gangliosides (Guidry et al., 1997; de Haan et al., 1998).
Recent evidence suggests that CT specifically binds directly to
antigen-presenting cells (APCs) through GM1–ganglioside inter-
action and induces nuclear translocation of nuclear factor
(NF)-kB, leading to DC maturation and activation (Kawamura
et al., 2003). Therefore, LTB may not only be useful as a carrier
for mucosal immunizations because of their M-cell interaction
in the Peyer’s patches, but also more generally as an immuno-
modulating APC-targeting molecule. Although LTB without LTA
exhibits reduced antigenicity (Horner et al., 1998; Bagley et al.,
2002, 2003), LTB may be used as an effective carrier by fusing
the vaccine antigen to LTB without the toxic A subunit.
In this study, we report the expression of the human tumour-
associated antigen MUC1 tandem repeat peptide and its fusion
to the mucosal carrier peptide LTB (LTB-MUC1) in a plant
expression system. Utilizing the magnICONTM-deconstructed
viral vector system, we efficiently produced LTB-MUC1 that was
post-translationally modified. LTB-MUC1 was glycosylated, and
a MUC1-specific monoclonal antibody detected the glycosylated
forms of LTB-MUC1, but not the nonglycosylated form. We
immunized MUC1.Tg mice with the magnICONTM-expressed
LTB-MUC1 and showed breach of MUC1 self-antigen tolerance.
To our knowledge, this is the first study to report the expression
of a human breast cancer tumour-associated antigen in a plant
system and its success in breaking self-antigen tolerance in a
transgenic mouse model.
Results
Nucleic acid analysis of agroinfiltrated plants
MagnICONTM transient expression was performed with one of
the 3¢ module constructs pICH-LTB, pICH-LM1 or pICH-LM1His
(Figure 1a) co-delivered with the 5¢ module pICH15879 and the
integrase module pICH14011 (Figure 1a) into N. benthamiana
(a)
(b)
Figure 1 magnICONTM viral vector transient expression system. (a) Dia-
grammatic representation of magnICONTM pro-vector modules used in
this study. Hsp81.1 represents the Arabidopsis heat shock protein 81.1
promoter; Integrase, Streptomyces phage PhiC31 integrase; AttP and
AttB, PhiC31 integrase recombination sites; Act2, Arabidopsis actin 2
promoter; RdRP, RNA-dependent RNA polymerase; MP, movement pro-
tein; LTB, synthetic LTB gene; LTB-G-MUC1, LTB gene with the GPGP
linker and the MUC1 tandem repeat; LTB-G-MUC1-6His, LTB-G-MUC1
gene with a histidine tag on the C-terminus of MUC1; GFP, green fluo-
rescent protein; LTBHis, LTB gene with the SGPS linker and a histidine
tag, 3¢NTR, 3¢ untranslated region; NosT, nopaline synthase terminator,
Int, intron; LB and RB, left and right borders of the T-DNA region. (b)
Northern analysis of Nicotiana benthamiana infiltrated with magnI-
CONTM pro-vector modules, for the detection of LTB-MUC1 mRNA.
Lanes: 1–2, N. benthamiana infiltrated with pICH-LM1; 3, N. benthami-
ana infiltrated with pICH-LTB; W.T., noninfiltrated N. benthamiana
control. Bottom panel is the methylene blue-stained membrane for
loading control: 10 lg of total RNA was loaded for each sample.
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leaves. Northern blot analysis for leaves infiltrated with pICH-
LM1His (Figure 1b, lanes 1 and 2) exhibits a band at approxi-
mately 1.2 kb, while leaves infiltrated with pICH-LTB (lane 3)
showed bands that are slightly lower (approximately 1.0 kb).
No bands are present in the wild-type control lane. Therefore,
the magnICONTM vectors produced correct transcripts with no
detectable truncations or degradation products.
LTB-MUC1 expression in agroinfiltrated plants
Nicotiana benthamiana leaves infiltrated with pICH-LM1 were
evaluated for LTB-MUC1 expression at different time points
[7, 9 and 11 days postinfiltration (dpi)] to determine the opti-
mum harvest time (Figure 2). Slight necrosis was apparent in
LTB-MUC1-expressing leaves 9 dpi, with complete necrosis at
infiltration sites by day 11 (Figure 2a), yet leaves infiltrated with
pICH-GFP remained healthy throughout the 11-day time course.
The necrosis indicates that LTB-MUC1 expression was toxic to
the leaf tissue, which was observed in another study that
expressed hepatitis B core antigen using the magnICONTM sys-
tem (Huang et al., 2006). We found that expression of unfused
LTB (without MUC1) induced earlier and stronger necrosis than
LTB-MUC1 (data not shown), which suggests that the toxic
effect of LTB-MUC1 is as a result of the LTB moiety.
Labile nontoxic B subunit levels in LTB-MUC1-expressing
leaves were 70 lg ⁄ g fresh weight (lg ⁄ g f.w.) at 7 dpi, dropped
to 38 lg ⁄ g f.w. on day 9 and then increased on 11 dpi to
88 lg ⁄ g f.w. (Figure 2b). MUC1 levels peaked at 7 dpi with
16 lg ⁄ g f.w. and then leveled off at 9 and 11 dpi with
12 lg ⁄ g f.w. (Figure 2c). The molecular mass ratio between
fusion partners LTB and MUC1 is 6 (12-kDa LTB vs. 2-kDa
MUC1), which is consistent with the observed lower levels of
MUC1 peptide than LTB. We cannot explain the difference in
expression level time courses for LTB vs. MUC1, but we suggest
that LTB may be more stable during later stages of tissue degra-
dation (Figure 2a). The tissue necrosis is probably due to the
hypersensitive response that plants use to combat pathogen
infection (Mur et al., 2008). This process involves an oxidative
burst and induces a series of biochemical responses, including
the release of serine proteases (Antao and Malcata, 2005)
which could result in cleavage to remove MUC1 from LTB.
Because we used a ganglioside capture ELISA for both LTB and
MUC1 detection, a cleavage of MUC1 from LTB would result in
the lower levels of MUC1 compared to LTB detected on 11 dpi.
From these results, we concluded that 7 dpi was the optimum
harvest time for LTB-MUC1 expression with the magnICONTM
system.
To facilitate purification of the LTB-MUC1 fusion protein, we
fused a 6His-tag to the C-terminus of the MUC1 gene to create
the pICH-LM1His pro-vector module. We also constructed the
pICH-LTBHis pro-vector module that contained a C-terminal
short linker and 6His-tag. The LTB-6His and LTB-MUC1-6His
proteins were transiently expressed in N. benthamiana, followed
by metal affinity purification. Purified proteins were analysed by
SDS–PAGE and Western blots for LTB, His and MUC1
(Figure 3a–c, respectively). The anti-LTB probe for LTB-MUC1
showed a protein at the expected 16 kDa size, and two unex-
pected proteins at approximately 18 and 20 kDa (Figure 3,
Lanes LM1). The anti-His and anti-MUC1 probes detected the
18- and 20-kDa proteins (Figure 3b,c), but not the 16-kDa pro-
tein. MagnICONTM-expressed LTB (Figure 3) showed the
expected 12-kDa protein with anti-LTB and anti-His probes, but
no 18- or 20-kDa species, and no reaction with the anti-MUC1
probe. These observations indicate that the unexpected 18- and
20-kDa proteins were because of the MUC1 peptide, which
may have been post-translationally modified.
Because MUC1 is a highly glycosylated protein in humans and
has a total of five Ser or Thr residues in the TR sequence (sites for
O-glycosylation), we decided to investigate whether the unex-
pected proteins resulted from glycosylation. In silico analyses
using NetNGlyc 1.0 predicted no potential N-glycosylation sites in
our LTB-MUC1 sequence. According to NetOGlyc 3.1, the LTB-
MUC1 construct has seven potential mucin type O-glycosylation
sites. However, a recent study showed that plants do not have
the enzymes necessary for mucin type O-glycosylation (Daskalova
et al., 2010). Thus, we expect that Ser ⁄ Thr sites are not utilized
in plants, where O-glycosylation occurs on hydroxyproline (Hyp)
residues. The LTB-MUC1-6His protein contains eight Pro residues
with the motifs xPxP and xPPxx, which may be recognized by
plant prolyl hydroxylases (Xu et al., 2008).
Hydroxyproline is a site for arabinogalactin type O-glycosyla-
tion, in which linear or branched oligosaccharides of arabinose
and ⁄ or galactose are attached to Hyp (Xu et al., 2008). To per-
form a thorough glycan analysis for the LTB-MUC1-6His fusion
protein, we prepared highly purified proteins. We employed
galactose affinity followed by metal affinity, which yielded
greater purity than metal affinity alone. The purified proteins
were separated by SDS–PAGE (Figure 4a), and excised bands
from the gel were dried, hydrolysed for 3 h with 2 M TFA and
the released monosaccharides were derivatized with anthranilic
acid. The amino acyl-sugars were analysed by RP-HPLC. On this
gel (Figure 4a), the LTB-MUC1-6His 20-kDa protein appeared to
(a)
(b) (c)
Figure 2 Time course of LTB-MUC1 expression in magnICONTM infil-
trated Nicotiana benthamiana. (a) Expression of GFP and LTB-MUC1 in
N. benthamiana 7, 9 and 11 days postinfiltration (dpi). Slight necrosis is
apparent in LTB-MUC1-expressing leaves 9 dpi, with complete necrosis
at infiltration site by day 11. Ganglioside capture ELISA was used to
quantify LTB (b) and MUC1 (c) expression at 7, 9 and 11 days postinfil-
tration. Expression levels reported in micrograms per gram fresh weight
(lg ⁄ g f.w.). Data are means of three independent leaf infiltrations ±SD.
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resolve a doublet, which were sampled together and referred
to as a 20 ⁄ 22-kDa band. Overlaid HPLC chromatograms of
AA-sugars from gel bands (16, 18 and 20 ⁄ 22 kDa) revealed
that the higher molecular weight proteins (18 and 20 ⁄ 22 kDa)
contained arabinose, whereas the lower molecular weight band
(16 kDa) contained much less sugar (Figure 4b, Table 1). No
sugars were present on LTB-6His peptide (Figure 4c, Table 1).
As depicted in Table 1, the 20 ⁄ 22-kDa protein contained the
highest amount of arabinose (2.19 nmol); the 18-kDa protein
contained a lower amount (1.70 nmol); the 16-kDa protein con-
tained the least amount of arabinose (0.44 nmol).
Fractions from LTB-MUC1-6His (sequence shown in
Figure 5a) were pooled and subjected to pronase digestion. An
MS ⁄MS spectrum of the glycopeptide GSTAOOAHG + 3 Ara,
where O designates Hyp, shows that the APP sequence contains
hydroxyproline and is furnished with a tri-arabinan (Figure 5b).
Pronase digestion of LTB-6His did not reveal any glycopeptides.
Pooled fractions of LTB-MUC1-6His were then subjected to
alkaline degradation with Ba(OH)2. The resulting amino acids
and glyco-amino acids were dansylated and analysed by car-
bon-LC-ESI-MS. The LC-MS result for LTB-MUC1-6His
(Figure 6a) showed Hyp (33%) and Ara-3Hyp (11%), which
eluted as isomeric peaks, while Pro (55%) eluted as a single
peak. LTB-6His did not show any arabinose residues,
although there were a number of hydroxylated prolines (26%,
Figure 6b).
Although pronase digestion revealed that the prolines (PP)
within the MUC1 sequence GSTAPPAHG are hydroxylated and
(a) (b) (c)
Figure 3 Western blot analysis of metal affinity-purified magnICONTM-expressed LTB-6His and LTB-MUC1-6His. (a) Anti-LTB antibody was used to
detect LTB-6His (lane LTB) and LTB-MUC1-6His (lane LM1). The LTB lane showed the LTB monomer at the expected molecular mass of 12 kDa as well
as a possible dimer at 24 kDa. The LM1 lane showed the expected size of the LTB-MUC1-6His monomer at 16 kDa, as well as two higher molecular
mass proteins at approximately 18 and 20 kDa. The protein detected at approximately 32 kDa may represent the dimer for the LTB-MUC1-6His. (b)
Nickel-conjugated HRP was used to detect LTB-6His (lane LTB) and LTB-MUC1-6His (lane LM1). The LTB lane showed the His-tagged LTB monomer at
12 kDa. The LM1 lanes only showed the higher molecular mass LTB-MUC1-6His proteins, approximately 18 and 20 kDa, but not the 16-kDa protein.
(c) Anti-MUC1 BC2 monoclonal antibody was used to detect LTB-6His (lane LTB) and LTB-MUC1-6His (lane LM1). No MUC1 protein was detected in
the LTB lane. Only the approximately 18 and 20 kDa of LTB-MUC1-6His were detected by the MUC1-specific antibody.
(a) (b)
(c)
Figure 4 Glycosylation analysis of LTB-Muc1-6His. (a) Coomassie-stained SDS–PAGE gel of purified LTB-6His (lanes 1 and 2) and LTB-MUC1-6His (lanes
4 and 5) protein fractions. Gel bands at approximately 12 kDa (LTB-6His) and 16, 18 and 20 ⁄ 22 kDa (LTB-Muc1-6His) were excised and hydrolysed
with TFA to release monosaccharides. (b) RP-HPLC of LTB-MUC1-6His shows a distinct peak for arabinose from the 20 ⁄ 22 and 18-kDa molecular
weight fractions, and a shorter peak from the 16-kDa fraction. An excised piece from the gel served as a negative control (Gel blank). (c) RP-HPLC of
LTB-6His does not show any monosaccharide peaks, suggesting the LTB is not glycosylated. The standard contained the following glycans: GlcN, Gluco-
samine; ManN, Mannosamine; GalN, Galactosamine; Gal, Galactose; Man, Mannose; Glc, Glucose; Ara, Arabinose; Xyl, Xylose. Gel blank was used as
a negative control.
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furnished with a tri-arabinan (Figure 5b), we note that there is
another GSTAPPA sequence at the C-terminal end near the
histidine tag, which also occurs in a context for O-linked
hydroxyproline arabinosylation, but was not detected by pron-
ase digestion. Interestingly, Hyp-Ara(3) modification to LTB-
MUC1-6His would only add approximately 0.5 kDa per site,
which is substantially less than the observed mobility shifts.
However, it is possible that carbohydrates may cause rather
unexpected effects in SDS–PAGE because of the nonbinding of
SDS. Another characteristic trait of glycosylated protein is the
heterogeneity in mobility, which results in broad bands in all
the Western blots of LTB-MUC1 compared to LTB alone. Thus,
although we cannot fully explain the mobility shifts of the
glycosylated species, we clearly showed that LTB-MUC1 protein
is glycosylated by O-linked hydroxyproline arabinosylation.
Systemic immunogenicity of purified LTB-MUC1-6His in
MUC1.Tg mice
As our main interest was to see whether a plant-derived human
cancer-associated antigen can mimic the authentic peptide and
be utilized as a vaccine candidate, we parenterally delivered the
LTB-MUC1-6His fusion protein to determine whether it could
break self-antigen tolerance and induce a MUC1-specific
response in a tolerant mouse model. We injected the plant-
derived LTB-MUC1-6His protein into MUC1.Tg mice. Because
we previously observed that the addition of CpG ODN to a vac-
cine formulation decreases the amount of antigen necessary to
induce an immune response (Pinkhasov et al., 2010), we also
tested the addition of 100 lg CpG ODN to the plant-derived
LTB-MUC1-6His (2–20 lg). The MUC1.Tg mice were immunized
on days 0, 7, 14 and 35. Serum analysis for anti-LTB IgG (data
not shown) and anti-MUC1 IgG (Figure 7a) showed responses
after the second immunization and a robust response after the
boost on day 35 for the CpG ODN (100 lg) + LTB-MUC1-6His
treatment group. Analysis of anti-MUC1 IgG1 and IgG2a
showed that there was a Th2 bias without CpG ODN (indicated
by a relatively high IgG1; no IgG2a detected in the no CpG
group; Figure 7b,c). However, addition of CpG ODN to LTB-
MUC1-6His pushed the response towards Th1 response, as
shown by substantial IgG2a production (Figure 7c). Anti-MUC1
antibody titres (IgG, IgG1 and IgG2a) in mice treated with CpG
ODN + LTB-MUC1 are significantly higher (P < 0.05) than the
PBS control group.
Discussion
Over the past 15 years, plants have become a promising alter-
native for producing recombinant proteins and potential thera-
peutics (Haq et al., 1995; Fischer et al., 1999; Mason et al.,
2002). In addition to the potential low cost, biological safety
and large-scale production advantage, plants are higher eukary-
otic organisms with an endomembrane system. Therefore, they
fold and assemble complex proteins using chaperones and
perform post-translational modifications similar to mammalian
systems (Ma et al., 2005). In this study, we investigated
whether the tumour antigen MUC1 fused to the mucosal-
targeting peptide LTB could be properly expressed in a plant
system. We employed a novel deconstructed viral vector system
known as magnICONTM (Marillonnet et al., 2004, 2005; Gleba
et al., 2005).
Table 1 Arabinose detected in each protein fraction of LTB-MUC1-
6His and LTB-6His
Sample Gel band nmol Arabinose ⁄ band
LTBMUC1 20–22 kDa 2.19
18 kDa 1.70
16 kDa 0.44
Gel blank 0.00
LTB 14 kDa 0.00
Gel blank 0.00
(a)
(b)
Figure 5 Pronase peptide analysis of LTB-MUC1-6His by MS and MS ⁄MS. (a) Amino acid sequence of LTB-MUC1-6His. Numbers at left indicate the
amino acid positions from the N-terminus. The amino acid sequence GSTAPPAHG that is glycosylated with arabinose is bold ⁄ italic ⁄ dotted underlined;
the tri-arabinan is found on the double proline site within this sequence. Other prolines are bold ⁄ underlined, and double prolines are bold ⁄ double
underlined. (b) MS and MS ⁄MS analysis of pronase digestion products. LTB-MUC1-6His gel fractions were pooled and subjected to digestion with
pronase. One small peptide with the amino acid sequence GSTAPPAHG comprising proline residues 113 and 114 was identified with three arabinose
residues attached. This glycopeptide was only found in LTB-MUC1-6His samples but not in LTB-6His.
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The transient magnICONTM agroinfiltrated N. benthamiana
plants produced LTB-MUC1 at approximately 3% TSP. We
observed signs of toxicity as a result of LTB expression, which
has been previously reported in stable plant transformants–
expressing LTB (Mason et al., 1998). Overexpression of certain
proteins in transgenic plants can interfere with normal plant
processes and cause altered phenotype or cell death. This is
more evident in the magnICONTM viral vector system because
of extremely high expression levels. Although the magnICONTM
system has the potential to produce a protein of interest up to
80% TSP (Marillonnet et al., 2004), the actual amount pro-
duced depends on the specific protein and must be evaluated
on a case by case basis.
Labile nontoxic B subunit Western blot revealed that magnI-
CONTM-expressed LTB-MUC1-6His contained the expected 16-
kDa protein and two higher molecular weight proteins (18 and
20 kDa) that were not expected. These higher molecular weight
proteins could not be ascribed to variations in mRNA process-
ing, as Northern analysis (Figure 1b) showed only the expected
size transcripts. However, the plant-derived LTB is targeted to
the endoplasmic reticulum (ER) through its cleavable amino-
terminal signal peptide, which targets it to the periplasmic
space in E. coli (Mason et al., 1998). Within a plant system,
LTB-MUC1 is predicted to pass through the vesicular pathway
from the ER to the Golgi apparatus and to undergo post-
translational modifications.
Glycan analysis using RP-HPLC clearly showed that the high
molecular weight bands are glycosylated forms of LTB-MUC1
(Figure 4). Specifically, pronase digestion revealed the glycans
are tri-arabinans linked to hydroxyprolines within the MUC1
tandem repeat sequence GSTAPPAHG (Figure 5). These results
are consistent with the Hyp contiguity hypothesis (Kieliszewski
and Lamport, 1994), which defines general rules to predict Pro
hydroxylation and Hyp O-glycosylation. The target motif for
O-glycosylation consists of at least two [Ala ⁄ Ser ⁄ Thr ⁄Val]-Hyp
repeats, with two consecutive Hyp not separated by more than
11 amino acids (Tan et al., 2003). The Hyp contiguity hypo-
thesis predicts arabinosylation of contiguous Hyp residues and
galactosylation of clustered, noncontiguous Hyp residues.
O-Hyp glycosylation occurs in two distinct modes, Hyp arabi-
nosylation and Hyp galactosylation (Shpak et al., 2001). Hyp
arabinosylation results in short (usually 1–4 residues) neutral, lin-
ear oligosaccharides of L-arabinofuranose (Hyp-arabinosides).
Hyp galactosylation results in addition of much larger
arabinogalactan heteropolysaccharides (Hyp-polysaccharides).
Hyp-arabinosides have also been shown to enhance polyproline
II helix content, which have been implicated to contribute to
structural integrity and an increase in thermal stability of
hydroxyproline-rich glycoproteins (HRGPs; Owens et al., 2010).
A recent study showed Hyp ⁄ Pro conversion and O-linked arabi-
nosylation on a recombinant therapeutic protein expressed in
transgenic plants (Karnoup et al., 2005). In conjunction with
our study, these reports outline the significance of post-
translational modification of recombinant proteins in plant
systems and warrant more detailed characterizations in future
studies and applications.
Glycosylation is known to alter essential biological functions,
such as immunogenicity. The essential role glycosylation plays is
clearly seen in the human TAA MUC1. In breast cancer, MUC1
has shorter and less complex chains (core 1 type) compared to
the highly branched and extended chains (core 2 type) found in
normal cells, resulting in the apparent unmasking of the peptide
core and revealing immunodominant peptide sequences.
A recent study showed that a tumour cell line exhibited a
higher density of O-glycosylation, which was attached to 95%
of available sites, whereas MUC1 from milk was glycosylated
on 55% of the available sites (Hanisch and Muller, 2000). This
study challenges earlier studies suggesting that underglycosy-
lation of cancer cell MUC1 was because of both reduction in
glycan chain length and reduced density. The observations from
the recent study suggest that the altered glycosylation induces
a conformational change in the peptide backbone, which
(a)
(b)
Figure 6 Analysis of Ara-Hyp species in LT-MUC1-6His. (a) Carbon-
LC-ESI-MS analysis of LTB-MUC1-6His after alkaline degradation. A high
percentage of the prolines as hydroxyprolines (33%) or glycosylated
hydroxyprolines, mainly with a tri-arabinan (11% of total prolines) were
observed. Hyp and glyco-Hyp give two peaks containing different con-
formers. (b) Quantitative comparison of the content of Proline (Pro),
hydroxyproline (Hyp) and glycosylated hydroxyproline between LTB-6His
and LTB-MUC1-6His. Both samples contained proline and hydroxypro-
line. LTB-MUC1-6His contained more hydroxyproline than LTB-6His and
contained Ara-Hyp glycopeptides, mainly with three arabinose residues.
Ara2, Ara3 and Ara4 designate a Hyp with 2, 3 and 4 Ara residues,
respectively.
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reveals immunodominant epitopes. Other evidence points to
the importance of tumour-associated MUC1 glycopeptides. The
hypoglycosylated tumour-associated form of MUC1 contains
abnormal mono- and disaccharide antigens, such as Tn (Gal-
NAc-O-S ⁄ T) and T (Gal-GalNAc-O-S ⁄ T), which are not normally
exposed on healthy cells or tissues, conversely 90% of carcino-
mas express these tumour-associated peptides (Springer, 1997).
A recent study showed that incorporation of tumour-associated
Tn antigens on MUC1 TR peptides induced glycopeptides-
specific responses and boosted previously suppressed MUC1
peptide-specific T cell and antibody responses in the MUC1.Tg
mice (Ryan et al., 2009). It is of interest to note that Hyp arabi-
nosylation is also made up of short oligoarabinosides, which
may be similar to the shorter and less complex glycan chains
found on the tumour form of MUC1. If this explanation holds
true, we can then speculate that the glycosylation of LTB-
MUC1-6His alters the peptide backbone in a similar fashion,
thereby mimicking the tumour form of MUC1, and induces a
robust response capable of breaking self-antigen tolerance.
Our study with the anti-MUC1 BC2 monoclonal antibody
showed that the plant-expressed unglycosylated LTB-MUC1-6His
was not detected by BC2 (Figure 3c); thus, glycosylation is a
likely requirement for BC2 binding. This observation suggests
that in the unglycosylated form, the MUC1 epitope may
undergo alternative folding that diminishes its antigenicity. The
absence of signal at 16 kDa in the anti-His Western blot
(Figure 3b) supports this idea, because the 6His was attached to
the C-terminus of the MUC1 tandem repeat, and the 16-kDa
species bound to the metal affinity resin. Therefore, the post-
translation glycosylation of MUC1 might induce a conforma-
tional change in the polypeptide backbone that allows the
MUC1 and His epitopes to be available for antibody detection.
We tested the immunogenicity of LTB-MUC1-6His in a
human MUC1-tolerant mouse model. In the context of paren-
teral delivery, LTB serves as a carrier protein because small mol-
ecules with a molecular weight of <2–5 kDa are not usually
immunogenic, even when administered in the presence of
adjuvant. To generate an immune response to these com-
pounds, it is necessary to attach them to a protein or other
compound that is immunogenic, which in our case is LTB.
Animal studies using the MUC1.Tg mouse model injected with
the purified LTB-MUC1-6His with the adjuvant CpG ODN
(a)
(b)
(c)
Figure 7 Parenteral immunization of MUC1.Tg
mice with purified magnICONTM generated LTB-
MUC1-6His. (a) Serum analysis for MUC1-specific
IgG in MUC1.Tg mice treated with: phosphate
buffer saline vehicle control (PBS); 100 lg CpG
ODN (CpG); 100 lg CpG + LTB-MUC1-6His
(LM1CpG). Serum samples were derived from
blood drawn 1 week after each immunization
(days 0, 7 and 14) and boost (day 35). (b) Serum
MUC1-specific IgG1 and IgG2a (c) in MUC1.Tg
mice treated with: PBS; 100 lg CpG ODN (CpG);
LTB-MUC1-6His (LTB-MUC1); 100 lg CpG + LTB-
MUC1-6His (CpG + LTB-MUC1). Anti-MUC1
titres (IgG, IgG1 and IgG2a) in mice treated with
CpG + LTB-MUC1 are significantly higher
(P < 0.05) than the PBS control group. Individual
mouse data are shown (n = 3–5 mice per
group).
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showed anti-MUC1 IgG, IgG1 and IgG2a responses (Figure 7a–c,
respectively).
To our knowledge, this is the first report to demonstrate
expression of a breast cancer antigen in a plant system. After
immunization of the MUC1-tolerant mouse with the plant LTB-
MUC1-6His antigen, we observed abrogation of self-antigen
tolerance. Breaking immune tolerance is a remarkable achieve-
ment in a cancer vaccine and illustrates that a plant-derived
tumour-associated antigen is equivocal to the human antigen in
the context of immune recognition. This study supports the uti-
lization of plants as an alternative production system for thera-
peutic and vaccine formulations.
Experimental Procedures
LTB-MUC1 design and expression plasmid construction
The MUC1 TR antigen (MUC1—STAPPAHGVTSAPDTRPAPGST-
APPA) contains the H-2Db MHC class I–restricted immunodomi-
nant epitope (APGSTAPPA) and the H-2Kb restricted epitope
(SAPDTRPAP). We modified the MUC1 coding sequence to con-
tain codons preferred by dicotyledonous plant genes, eliminate
aberrant mRNA processing and destabilization signals, and mini-
mize secondary structure hairpins. To decrease the chance of
steric hindrance in the fusion protein, the linker Gly-Pro-Gly-Pro
(GPGP) was inserted between the LTB and MUC1 sequences.
The GPGP-MUC1 coding sequence was constructed using four
oligonucleotides, each approximately 50 bp long that, upon
annealing and assembly of the nucleotides as described by
Stemmer et al. (1995), contained a 5¢ blunt end and a 3¢ KpnI
restriction site. The pLTB-L-plasmid (Walmsley et al., 2003) con-
taining the plant-optimized LTB sequence was prepared for
insertion of the GPGP-MUC1 peptide by cutting and blunting
the BbsI site, followed by digestion with KpnI. The LTB-MUC1
fusion gene is deposited in GenBank accession number
DQ854816.
The magnICONTM expression system is based on in planta
assembly of functional viral vectors from separate pro-vector
modules previously described by Marillonnet et al. (2004). The
integrase module pICH14011 and the 5¢ module pICH15879
are shown in Figure 1a. The 3¢ module pICH-LTB contains the
LTB gene inserted into the multiple cloning site of the
pICH11599 module (Marillonnet et al., 2004). The LTB-MUC1
gene from pJPLM1 was cut with KpnI ⁄ BglII, blunted at the KpnI
site with T4 DNA polymerase and inserted into pICH-LTB cut
with BamHI ⁄ BglII and blunted at the BamHI site, generating
pICH-LM1 (Figure 1a). The His-tagged LTB-MUC1 fusion gene
was generated by PCR using pICH-LM1 as the template and the
reverse primer MHisRev (5¢-AAGTCTGCAGTTAATGGTGATGGTG
ATGATGGTGTGCAGGTGGTGCAGTAG-3¢), which contains seg-
ments of the C-terminus of the MUC1 gene (underlined) along
with 6His sequence (italicized) and a PstI restriction site (bold) and
the forward primer nosR (5¢-TGCGGTTCTGTCAGTTCCAAA-3¢).
The resulting PCR fragment and the vector pICH-LTB were cut
with NcoI ⁄ PstI and ligated to generate pICH-LM1His (Figure 1b).
The His-tagged LTB gene was constructed by PCR using
pICH-LM1 as the template and the reverse primer LTB6H-Sac
(5¢-GGGAGCTCTTAATGGTGATGGTGATGGTGACTAGGTCCGGA-
GTTCTCCATGCTGATGGC), which introduces a 3¢ SacI site, a
6His sequence and the linker ‘SGPS’, and the forward primer
nosR. The resulting PCR product and pICH11599 were digested
with NcoI and SacI and ligated to make pICH-LTBHis.
Agroinfiltration procedure for magnICONTM viral
vector transformation
The magnICONTM pro-vector modules containing the LTB-
MUC1 gene (Figure 1a) were prepared from cultures of E. coli
DH5a and electroporated into Agrobacterium tumefaciens strain
GV3101. The Agrobacterium containing the pro-vector modules
were grown in YENB medium (7.5 g ⁄ L yeast extract, 8 g ⁄ L
nutrient broth) supplemented with rifampicin (60 mg ⁄ L) and
carbenicillin (50 mg ⁄ L) at 28 !C. Overnight cultures
(OD600 = 0.5–1.0) were adjusted to a final OD600 of 0.1, and
equal volumes of the pro-vector modules (integrase, 5¢ module,
3¢ module 1 : 1 : 1) were mixed, sedimented (5 min, 5000 g)
and resuspended in infiltration buffer (10 mM MES, pH 5.5 and
10 mM MgSO4) at 0.1 OD600. Leaves of greenhouse-grown
N. benthamiana were infiltrated using a syringe without a nee-
dle as described previously (Huang et al., 2006).
Nucleic acid analysis
Total RNA samples were isolated from 500 mg of leaf tissue
using RNAqueous (Ambion, Austin, TX) and Plant RNA isolation
Aid (Ambion, Austin, TX). The RNA samples were quantified
spectrophotometrically. Ten micrograms of total RNA was dena-
tured with formaldehyde ⁄ formamide, electrophoresed on a 1%
agarose MOPS-acetate-EDTA gel, capillary transferred to a Zeta
probe membrane (Bio-Rad Laboratories, Hercules, CA) as
described by Sambrook and Maniatis (1981) and fixed by UV
cross-linkage. The membrane was then washed in 5% acetic
acid, stained with 0.25% methylene blue in 0.3 M sodium
acetate (pH 5.2) and destained with RNase-free water. Hybridi-
zation and membrane detection were performed as per the
manufacturer’s instructions using an LTB-MUC1-specific probe
(DIG wash and block buffer set and DIG Luminescent Detection
Kit; Roche Applied Sciences, Indianapolis, IN) using a probe con-
centration of 5 lL ⁄mL. Labelled membranes were visualized
after exposing to KODAK BioMax MS film.
Metal affinity purification of His-tagged LTB-MUC1
His-tagged LTB-MUC1 fusion protein was purified using TALON
Metal Affinity Resin (BD Clontech, Mountain View, CA) at 4 !C
under gravity. Ten grams of fresh leaf material was snap-frozen
with liquid N2 and homogenized in a mortar and pestle with
40 mL lysis buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 0.5%
CHAPS) and one tablet of Complete, Mini, EDTA-Free Protease
Inhibitor Cocktail (Roche Applied Sciences, Indianapolis, IN),
transferred to 50-mL Falcon tubes and kept on ice for 10 min.
After 15-min centrifugation (5000 g), supernatant was filtered
with Miracloth (Calbiochem, San Diego, CA) and then with 0.45-
lm filters. Filtered supernatant was added to TALON resin (2 mL
bed volume) equilibrated previously with lysis buffer in a 25-mL
chromatography tube. The flow through was passed through
the column twice before discarding. Columns were washed with
ten volumes of wash buffer (20 mM Tris, pH 8.0, 500 mM NaCl,
5 mM imidazole, 0.5% CHAPS) and then eluted with six volumes
of elution buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 150 mM
imidazole, 0.5% CHAPS). Eluted fractions were desalted and
then concentrated with the Pierce iCON Protein Concentrator 9K
MWCO (Thermo Fisher Scientific, Rockford, IL).
Galactose affinity chromatography
Leaf material was homogenized in a blender with ice-cold
extraction buffer [20 mM sodium phosphate buffer (pH 7.4),
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150 mM NaCl, 0.1 M sodium ascorbate, SigmaFastTM Protease
Inhibitor Cocktail Tablet (Sigma-Aldrich, St. Louis, MO), 0.1%
Triton]. Used 500 mL extraction buffer per 100 g leaf material.
The plant material was then spun on ice for 30 min, to allow
full homogenization. The material was then filtered through
cheese cloth and centrifuged at 8000 g for 20 min. Transferred
the supernatant into a new tube (trying not to disturb the pel-
let) and spun again for 20 min at 8000 g. Used Immobilized
D-Galactose (Thermo Fisher Scientific, Rockford, IL) for galactose
column and equilibrated with buffer (20 mM sodium phosphate
buffer (pH 7.4), 150 mM NaCl). The plant supernatant was then
run through the column at 4 !C, and the flow through was col-
lected. The column was washed ten times the bed volume with
buffer [20 mM sodium phosphate buffer (pH 7.4), 150 mM NaCl]
and eluted with five volumes of elution buffer (600 mM galac-
tose, 20 mM sodium phosphate buffer (pH 7.4), 150 mM NaCl).
The eluted fractions were then further purified using the Talon
metal affinity column as described above.
Acetone precipitation
The purified LTB-6His and LTB-MUC1-6His were precipitated
with acetone prior to shipment and further glycan analysis. To
precipitate the protein samples, we added five times the sample
volume of cold acetone. The tube was vortexed and then incu-
bated for 1 h at )20 !C. The samples were then centrifuged
for 10 min at max speed (14 000 g). The supernatant was dis-
posed of, and the pellet was allowed to air dry at room temper-
ature for 30 min.
Ganglioside capture ELISA
Ganglioside-dependent ELISA was performed according to Haq
et al. (1995). Volumes of 50 lL in microtiter plates (Costar
3590; Fisher Scientific, PA) were used throughout. Samples
were assayed in two replicates of varying dilutions in PBSTM
(1% dry milk + PBS + 0.05% Tween-20) of each extract. Plates
were washed three times with PBST (PBS + 0.05% Tween-20)
and incubated with either 1 : 1000 rabbit anti-LTB serum
(Benchmark Biolabs, Overland Park, KS) or mouse anti-MUC1
monoclonal antibody BC2 (Xing et al., 1989) in PBSTM for 1 h
at 37 !C. Wells were incubated with goat anti-rabbit IgG–horse-
radish peroxidase (HRP) conjugate (Sigma, St Louis, MO) diluted
1 : 12 000 in PBSTM for 1 h at 37 !C and developed with TMB
Peroxidase EIA Substrate kit (Bio Rad, Hercules, CA) for 5 min
at 23 !C. Absorbance at 450 nm was measured, and ELISA data
were converted to micrograms LTB per gram of fresh weight by
reference to a standard curve constructed using purified bacte-
rial LTB (provided by Benchmark Biolabs). Although ganglioside-
dependent ELISA was used for detecting MUC1 in the plant
samples, the MUC1 standards were directly bound to the
plates. The standard for MUC1 detection was a synthetic
MUC1 tandem repeat peptide (cys-STAPPAHGVTSAPDTRPAPGS-
TAPPA) synthesized at Arizona State University, Department of
Biochemistry, Tempe, AZ.
Western blot to detect LTB-MUC1
Western analysis to detect LTB and MUC1 from plant protein
extract was performed as described by Walmsley et al. (2003).
The membrane was blocked with 3% PBSTM (3% dry
milk + PBS + 0.1% Tween-20) overnight, and LTB was detected
with rabbit anti-LTB serum (1 : 5000 dilution in 1% PBSTM),
followed by an anti-rabbit IgG–HRP (1 : 9000 in 1% PBSTM;
Sigma). To detect MUC1, we used the MUC1-specific antibody
BC2 (Xing et al., 1989) (1 : 5000 dilution in 1% PBSTM), fol-
lowed by an anti-mouse IgG–HRP conjugate (1 : 8000 dilution
in 1% PBSTM; Pierce Biotechnology, Rockford, IL). To detect
the 6His-tag, we used nickel-conjugated HRP (Pierce ⁄ Thermo
Scientific HisProbe-HRP, product #15165, 1 : 1000 dilution in
1% PBSTM). Detection was performed using the Amersham
ECL + kit (Bio-Rad Laboratories) as per manufacturer’s
instructions.
In silico analyses
To determine whether our LTB-MUC1 construct has potential
N-glycosylation sites, we used the NetNGlyc 1.0 server, which
predicts N-glycosylation sites in human proteins using artificial
neural networks that examine the sequence context of Asn-Xaa-
Ser ⁄ Thr sequons (http://www.cbs.dtu.dk/services/NetNGlyc/). To
determine whether our LTB-MUC1 has potential O-glycosyation
sites on Ser ⁄ Thr residues, we used NetOGlyc 3.1 server, which
produces neural network predictions of mucin type GalNAc-O-
glycosylation sites in mammalian proteins (http://www.cbs.dtu.
dk/services/NetOGlyc/).
Monosaccharide analysis
Samples were purified by galactose affinity followed by metal
affinity chromatography, and then subjected to SDS–PAGE,
Coomassie-stained bands were excised, dried, hydrolysed for
3 h with 2 M TFA and the released monosaccharides were deriv-
atized with anthranilic acid. The labelled sugars were analysed
by reverse-phase high-performance liquid chromatography
(RP-HPLC) with fluorescence detection (Anumula KR, 1994 Anal.
Biochem.). Blank gel pieces were used as background controls.
Amino acid analysis for the presence of Hyp and
glycosylated Hyp
Samples were subjected to SDS–PAGE, and the stained bands
were then excised. Excised bands were pooled and then sub-
jected digestion with pronase, which has a very low specificity
and hence generates small, overlapping peptides. This was fol-
lowed by analysis using MS and MS ⁄MS. For alkaline degrada-
tion, the samples were pooled and then dissolved and
subjected to degradation with Ba(OH)2. The resulting amino
acids and glyco-amino acids were dansylated and analyzed by
carbon-LC-ESI-MS (Leonard et al., 2010).
Parenteral immunization with purified
magnICONTM-expressed LTB-MUC1-6His
MUC1.Tg mice (6–8 weeks old) were bred in-house (Rowse
et al., 1998) at the Mayo Clinic Scottsdale Natalie Schafer
Transgenic Animal Facility in pathogen-free conditions. Groups
of mice (n = 5) were injected intraperitoneally (i.p.) with
2–20 lg of LTB-MUC1-6His, or 2–20 lg LTB-MUC1-6His + 100
lg CpG ODN (1826; Coley Pharmaceutical Group, Wellesley,
MA). Control groups were injected i.p. with PBS (pH 7.4), or
100 lg CpG ODN or control plant extract purified with TALON
Resin. Mice were immunized on days 0, 7, 14 and 35. Tail
blood from individual mice was collected on a weekly basis until
termination (day 70).
Determination of IgG, IgG1 and IgG2a titres in serum
ELISA plates (Falcon #353911; BD Biosciences Discovery Lab-
ware, Bedford, MA) were coated with 5 lg ⁄50 lL ⁄well of the
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chemically synthesized MUC1 peptide in PBS and incubated
overnight at 37 !C. After three washes with PBST, plates were
blocked with 10% foetal calf serum (FCS) in PBS for 1 h at
37 !C. Serum samples were serially diluted in the plates using
10% FCS ⁄ PBS, starting at 1 : 20. The plates were incubated for
1 h at 37 !C before washing and incubation with goat anti-
mouse IgG–HRP (Pierce Biotechnology), diluted 1 : 20 000 in
10% FCS ⁄ PBS, for 1 h at 37 !C. For IgG1 and IgG2a, the
plates were incubated with HRP-conjugated goat anti-mouse
IgG1 or anti-mouse IgG2a antibodies (Southern Biotech, Bir-
mingham, AL), diluted 1 : 2000 in 10% FCS ⁄ PBS, for 1 h at
37 !C. Plates were developed with TMB peroxidase substrate
(Bio-Rad Laboratories) for 5 min. The reaction was stopped with
1 N H2SO4, and the absorbance read at 450 nm. Concentra-
tions of serum anti-MUC1 were determined by linear regression
from a standard curve of BC2, a mouse monoclonal antibody
with epitopes in the tandem repeat (TR) domain on MUC1
(Xing et al., 1989). The anti-LTB antibody ELISA was performed
as described for the anti-MUC1 ELISA except plates were
coated with ganglioside (Sigma-Aldrich G3018) 0.5 lg ⁄ 50 lL
per well and incubated overnight at 23 !C, before adding
125 ng of LTB in 50 lL per well (Benchmark Biolabs). Concen-
trations of serum anti-LTB were determined by linear regression
from a standard curve of rabbit anti-LTB, which was purified
using the HiTrap Protein G HP affinity column (Amersham Bio-
sciences, Piscataway, NJ), and then quantified for protein con-
centration using absorbance at 280 nm. Data are presented as
units ⁄ml, where 1 unit is defined as 1 ng ⁄mL rabbit anti-LTB
IgG equivalent.
Statistical analysis
For the parenteral immunization study, Fisher’s exact test was
applied to determine the incidence of MUC1-specific antibody
concentrations between the PBS and CpG ODN control groups
to the LTB-MUC1 and LTB-MUC1 + CpG ODN treatment
groups. Results were considered statistically significant if
P < 0.05.
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